Padmanabh P. Bhatt Sells 700 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN traded down $0.15 during midday trading on Wednesday, reaching $39.00. 255,211 shares of the company traded hands, compared to its average volume of 331,395. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 36.45 and a beta of 0.90. The company has a fifty day moving average price of $36.98 and a 200 day moving average price of $34.32. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) EPS. On average, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald began coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target for the company. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Stephens Investment Management Group LLC raised its position in shares of Supernus Pharmaceuticals by 1.8% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after buying an additional 33,710 shares in the last quarter. Pacer Advisors Inc. increased its stake in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after acquiring an additional 403,028 shares during the period. Geode Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Supernus Pharmaceuticals by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after purchasing an additional 7,833 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after purchasing an additional 91,354 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.